Skip to Main Content

Paper Details

Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy: Payer Approvals and Rejections, and Patient Characteristics for Successful Prescribing.
Circulation
43
2017
Kexin, PCSK9i, Patient, Proprotein Convertase, Proprotein convertase subtilisin/kexin type 9, Subtilisin, atherosclerotic cardiovascular disease, cholesterol, familial hypercholesterolemia, low-density lipoprotein cholesterol, patients, statin
Author NameAffiliation
Pradeep NatarajanLeonard Davis Institute of Health Economics, University of Pennsylvania, A.F.). Center for Genomic Medicine and Cardiovascular Research Center, Massachusetts General Hospital, Broad Institute of Harvard and Massachusetts Institute of Technology, MA (P.N.). Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center
Kamil F FaridiLeonard Davis Institute of Health Economics, University of Pennsylvania, A.F.). Center for Genomic Medicine and Cardiovascular Research Center, Massachusetts General Hospital, Broad Institute of Harvard and Massachusetts Institute of Technology, MA (P.N.). Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center
Robert W YehLeonard Davis Institute of Health Economics, University of Pennsylvania, A.F.). Center for Genomic Medicine and Cardiovascular Research Center, Massachusetts General Hospital, Broad Institute of Harvard and Massachusetts Institute of Technology, MA (P.N.). Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center
  • 1 - 3

Datasets

Release 1.2